Notice: This company has been marked as potentially delisted and may not be actively trading. Deciphera Pharmaceuticals (DCPH) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Get the Latest News and Ratings for DCPH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Deciphera Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up DCPH Analyst Ratings Over TimeTypeCurrent Forecast11/22/23 to 11/21/241 Month Ago10/23/23 to 10/22/243 Months Ago8/24/23 to 8/23/241 Year Ago11/22/22 to 11/22/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)3 Buy rating(s)3 Buy rating(s)8 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)7 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$23.24$24.17$24.17$22.56Forecasted Upside-9.18% Downside-5.54% Downside-5.54% Downside85.95% UpsideConsensus RatingHoldHoldHoldModerate Buy Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide DCPH Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History DCPH Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Deciphera Pharmaceuticals Stock vs. The CompetitionTypeDeciphera PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.13 2.80 2.50Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-9.18% Downside26,931.54% Upside9.83% UpsideNews Sentiment RatingNeutral NewsSee Recent DCPH NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails4/30/2024Guggenheim3 of 5 stars Reiterated RatingBuy ➝ Neutral4/30/2024JMP Securities2 of 5 stars Reiterated RatingMarket Outperform ➝ Market Perform4/30/2024Barclays3 of 5 stars UpgradeUnderweight ➝ Equal Weight$9.00 ➝ $26.00+2.85%4/29/2024Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. BerensSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/29/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Hold$26.00 ➝ $25.60+1.55%4/29/2024JonestradingSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Hold$25.60+1.55%3/20/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetNeutral ➝ Neutral$14.00 ➝ $16.00+2.24%2/7/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$22.00 ➝ $23.00+64.05%10/31/2023HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$25.00 ➝ $30.00+151.47%10/30/2023Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeNeutral ➝ Overweight$18.00 ➝ $23.00+82.54%2/7/2023Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform$28.00 ➝ $30.00+79.53%1/25/2023CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform$25.00 ➝ $30.00+66.20%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:26 AM ET. DCPH Forecast - Frequently Asked Questions What is Deciphera Pharmaceuticals' forecast for 2025? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Deciphera Pharmaceuticals is $23.24, with a high forecast of $26.00 and a low forecast of $16.00. Should I buy or sell Deciphera Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" DCPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares. Does Deciphera Pharmaceuticals's stock price have much downside? According to analysts, Deciphera Pharmaceuticals's stock has a predicted downside of -9.18% based on their 12-month stock forecasts. Do Wall Street analysts like Deciphera Pharmaceuticals more than its competitors? Analysts like Deciphera Pharmaceuticals less than other "medical" companies. The consensus rating for Deciphera Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DCPH compares to other companies. Stock Forecasts and Research Tools Related Companies Xencor Stock Forecast Syndax Pharmaceuticals Stock Forecast Seres Therapeutics Stock Forecast Intra-Cellular Therapies Stock Forecast Roivant Sciences Stock Forecast Ascendis Pharma A/S Stock Forecast Legend Biotech Stock Forecast Elanco Animal Health Stock Forecast Blueprint Medicines Stock Forecast Nuvalent Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin This page (NASDAQ:DCPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Deciphera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
